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February 16, 2010:700–3nd cardiovascular risk factors were confirmed to play a role in the
athophysiology, it would be important to clearly identify and treat
hem with a view to preventing recurrence (1,2,5).
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Pre-Morbid Psychiatric and Cardiovascular HistoryTable 1 Pre-Morbid Psychiatric and Cardiovascula
Variable
ABS
(n  2
Anxiety 14 (56
Depression 12 (48
Anxiety or depression 17 (68
Substance abuse 5 (20
History of emotional or physical abuse 4 (16
Total psychiatric diagnoses 1.40 1
Family history of anxiety or depression 11 (44
Hypertension 19 (76
Hyperlipidemia 13 (52
Diabetes mellitus 4 (16
Former or current smoking history 18 (72
Total cardiovascular risk factors 2.68 1
Values are n (%) or mean  SD. *p  0.01 for comparison with patie
ABS  apical ballooning syndrome; STEMI  ST-segment elevationdoi:10.1016/j.jacc.2009.10.031
erformed a study of 54 patients (mean age 68 years, 79% men)
w
c
d
d
t
m
t
t
d
d
e
m
w
u
*
P
DEFERENCES
. Bybee KA, Prasad A. Stress-related cardiomyopathy syndromes. Cir-
culation 2008;118:397–409.
. Prasad A, Lerman A, Rihal CS. Apical ballooning syndrome (Tako-
Tsubo or stress cardiomyopathy): a mimic of acute myocardial infarc-
tion. Am Heart J 2008;155:408–417.
. Wittstein IS, Thiemann DR, Lima JAC, et al. Neurohumoral features
of myocardial stunning due to sudden emotional stress. N Engl J Med
2005;352:539–48.
. Everson-Rose SA, Lewis TT. Psychosocial factors and cardiovascular
diseases. Annu Rev Public Health 2005;26:469–500.
. Roy-Byrne PP, Davidson KW, Kessler RC, et al. Anxiety disor-
ders and comorbid medical illness. Gen Hosp Psychiatry 2008;30:
ory
STEMI
(n  25)
General Control Subjects
(n  50)
3 (12%)* 9 (18%)*
7 (28%) 11 (22%)
9 (36%)† 15 (30%)*
2 (8%) 3 (6%)
0 (0%)† 1 (2%)†
0.52 0.71* 0.54 0.89*
1 (4%)* 7 (14%)*
19 (76%) 30 (60%)
18 (72%) 32 (64%)
5 (20%) 7 (14%)
12 (48%) 17 (34%)*
2.52 1.19 1.88 1.27†
ABS. †p  0.05.
rdial infarction.208–25.Letters to the Editorurther Barriers to Conversations
bout Deactivation of Implantable
ardioverter-Defibrillators
e read the recent report by Goldstein et al. (1) with interest.
heir study polled 147 doctors who looked after patients with
mplantable cardioverter-defibrillators (ICDs) regarding perceived
arriers to end-of-life discussions with these patients. Although it
llustrates that doctors have a high degree of confidence in their
kills in end-of-life discussions with ICD patients, we believe that
octors may in general be substantially overestimating patients’
evel of understanding of the device.
In the report by Goldstein et al. (1), for instance, 93% of the
ardiologists believed that their patients understood why they had
n ICD. Most clinicians also believed that patients knew the ICD
ould be deactivated. Our own data, which is from the patient
erspective, suggests a far poorer understanding of their ICDs. Weith an ICD in situ for chronic heart failure. None had a
ombined device for biventricular pacing.
Patients had a generally disappointing understanding of the
evice. Only 38% of patients were aware that the device could be
eactivated without being explanted. Only 65% of patients felt
hey understood the device as well as they would like to in order to
ake decisions. In fact, although 85% of patients understood that
he device administered a shock, only 65% of patients understood
hat function of the device was solely to prevent sudden cardiac
eath rather than to improve symptoms.
Toward the end of the life of a patient with heart failure, the
evice can deliver painful and frightening shocks. Timely consid-
ration and discussion of deactivation may allow this period to be
ore peaceful and natural.
However, if the patient does not understand how the device
orks, and the doctor does not realize that the patient does not
nderstand, how can such a discussion be effective?
Claire Raphael, MA, BSc
rapa Kanagaratnam, PhDr Hist
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e thank Dr. Raphael and colleagues for their interest in our
eport (1). The investigators report their own findings, which
emonstrate that patients with implantable cardioverter-
efibrillators have relatively poor understanding of their device as
t relates to options for deactivation. Their findings confirm our
revious qualitative work with patients as well (2). The investiga-
ors point out that if physicians think patients understand options
or deactivation, but in reality they do not, then this can be a reason
hat discussions about deactivation occur so rarely. We are in
omplete agreement with these investigators and did mention in
ur original contribution that this apparent incongruity between
hysician perception of patients’ knowledge and what patients’
ctually understand poses a challenge to communication about
eactivation. We thank Dr. Raphael and colleagues for highlight-
ng this important issue in their letter.
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ncidental Findings on
ardiac Computed Tomography
acHaalany et al. (1) recently reported that incidental findings
IFs) on computed tomography performed to diagnose coronary
rtery disease (CAD) are common but do not predict noncardiac
eath, and investigating them further “is not without cost or risk.”
Although we appreciate the detailed analysis of IFs and costs,
e believe a significant flaw affects the study design. Drawing
onclusions on whether mortality differs between patients with and
ithout IFs becomes statistically unsound if some patients receive
otentially lifesaving (or at least life-prolonging) interventions,
uch as lobectomy for lung carcinoma or chemotherapy for
ediastinal lymphoma. In other words, although Kaplan-Meier
urvival curves show no difference in survival between patients with
Fs and those without, any intervention that may prolong survival
eyond the reported follow-up time significantly impairs the
alidity of the analysis.
Moreover, the investigators recognize that an 18-month
ollow-up time may be inadequate to correctly evaluate indetermi-
ate IFs, as some of them may become significant with a longer
ollow-up time. We concur, but we also add that an 18-month
ollow-up time is probably inadequate even for the prognostic
valuation of the smaller number of IFs that were already signif-
cant, as they include disorders with a natural course that may be
onger than 18 months (2).
Further studies are certainly necessary to clarify whether any
enefit lies in further investigating indeterminate findings, but
rom the point of view of evidence-based medicine, that question
annot be answered by comparing a group of patients with IFs and
nother group without. A more appropriate study design would
xclude patients who already have a clear management pathway set
efore them (i.e., those without any IFs and those with an
mmediately significant IF) and randomize the remaining patients
ith indeterminate IFs to either further investigations or simple
ollow-up.
As the number of procedures increases, invasive cardiologists
ncreasingly will be called to acquire sufficient preparation to
onsider the global significance of imaging findings, and we
ppreciate the relevance of the work of MacHaalany et al. (1) in
hat direction.
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